auriculin การใช้

A few weeks later the company disclosed it had halted development of Auriculin after late-stage tests showed it wasn't effective.
Auriculin, at a cost of about $ 2, 000 per treatment, was thought to have a potential market of about $ 250 million a year.
As recently as February Casey was quoted in a company release, touting the " rapid clinical progress " of the drug, known as Auriculin.
Mountain View-based Scios Nova Inc . said its treatment for acute kidney failure, Auriculin, failed to show benefits for most patients treated during 27 months of clinical study.
In May, for example, Scios Nova Inc . lost 46 percent of its share value when it announced a clinical setback for its key kidney-failure compound, Auriculin.